Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Endovascular Engineering
Age
18–90
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Asterisks \* indicate entry criteria that can be evaluated during prescreening without obtaining informed consent as they are part of standard of care PE management. Asterisks in parenthesis (\*) indicate entry criteria that can be evaluated during prescreening without obtaining informed consent at Sites that routinely perform CTA as part of standard of care in PE management.
Patients must meet ALL of the following criteria to be eligible for participation in the study:
1. \*Patient is \> 18 and \< 90 years old
2. \*Clinical signs and symptoms consistent with acute submassive PE with duration ≤ 14 days, as determined by the Investigator
3. (\*)CTA evidence of proximal PE (filling defect in at least one main or lobar pulmonary artery)
4. (\*)RV/LV ratio of ≥ 0.9 (Enrollment qualification assessment based on Investigator's interpretation of RV/LV ratio at baseline)
5. \*Systolic blood pressure ≥ 90 mmHg (initial SBP may be ≥ 80 mmHg if the pressure recovers to ≥ 90 mmHg with fluids)
6. \*Heart rate \< 130 BPM prior to procedure
7. \*Patient is deemed medically eligible for interventional procedure(s), per investigator guidelines and clinical judgment
8. Patient signs a written Informed Consent form to participate in the study, prior to any study mandated procedures
You may not be if
Patients must be EXCLUDED from participation in this study if ANY of the following criteria are met:
1. \*Acute massive PE at presentation
2. \*Prior PE within last 6 months
3. \*Thrombolytic use within 30 days of baseline CTA
4. \*Pulmonary hypertension with peak pulmonary artery systolic pressure \> 70 mmHg by right heart catheterization
5. \*Vasopressor requirement after fluids to keep pressure ≥ 90 mmHg
6. \*FiO2 requirement \> 40% or \> 6 LPM to keep oxygen saturation \> 90%
7. \*Hematocrit \< 28% (NOTE: hematocrit required within 24 hours of index procedure)
8. \*Platelets \< 100,000/μL
9. \*Serum creatinine \> 1.8 mg/dL
10. \*International normalized ratio (INR) \> 3
11. \*aPTT (or PTT) \> 50 seconds on no anticoagulation
12. \*Major trauma \< 14 days
13. \*Presence of intracardiac lead in the right ventricle or right atrium placed within 6 months
14. \*Cardiovascular or pulmonary surgery within last 7 days
15. \*Life expectancy less than 1 year due to advanced malignancy, as determined by the investigator at the time of enrollment
16. \*Known bleeding diathesis or coagulation disorder
17. \*Known left bundle branch block
18. \*History of severe pulmonary arterial hypertension
19. \*History of chronic left heart disease with left ventricular ejection fraction ≤ 30%
20. \*History of uncompensated heart failure
21. \*History of underlying lung disease that is oxygen dependent
22. \*Presence of IVC filter and or iliocaval stents
23. \*History of heparin-induced thrombocytopenia (HIT)
24. \*Any contraindication to systemic or therapeutic doses of heparin or anticoagulants
25. \*Known anaphylactic reaction to radiographic contrast agents that cannot be pretreated
26. \*Known allergy to any device component
27. (\*)Imaging evidence or other evidence that suggests, in the opinion of the Investigator, the Subject is not appropriate for mechanical thrombectomy intervention (e.g., inability to navigate to target location, predominately chronic clot or non-clot embolus)
28. \*Life expectancy of \< 90 days, as determined by Investigator
29. \*Female who is pregnant or nursing
30. \*Current participation in another investigational drug or device treatment study
Clareo Health | Endovascular Engineering ENGULF Study
